Lumos Pharma(LUMO) - 2021 Q3 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other ...